Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Abbott Laboratories Begins Trial of Encantor System to Treat Aortic Stenosis

Abbott Laboratories Begins Trial of Encantor System to Treat Aortic Stenosis

MT newswireMT newswire2026/11/19 13:44
09:44 AM EST, 11/19/2026 (MT Newswires) -- Abbott Laboratories (ABT) said Thursday it has started a clinical trial evaluating the safety and efficacy of its investigational Encantor software-guided balloon-expandable transcatheter aortic valve implantation system to treat symptomatic severe aortic stenosis. The study will enroll up to 300 patients in Europe and Australia with symptomatic severe aortic stenosis caused by severe calcium buildup in the aortic valve, according to a statement. Abbott said it plans to initiate a pivotal trial in the US in the coming months.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix

According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.

华尔街见闻•2026/11/21 03:16

"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."

Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.

华尔街见闻•2026/11/21 02:16